State Street Corp Sells 1,805,779 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

State Street Corp trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 59.2% in the third quarter, Holdings Channel.com reports. The firm owned 1,246,613 shares of the company’s stock after selling 1,805,779 shares during the period. State Street Corp’s holdings in Zentalis Pharmaceuticals were worth $4,588,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the period. Carson Advisory Inc. grew its holdings in Zentalis Pharmaceuticals by 55.8% during the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after acquiring an additional 8,800 shares during the period. Erste Asset Management GmbH bought a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000. Finally, 49 Wealth Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 81.7% in the 3rd quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock worth $83,000 after purchasing an additional 10,145 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZNTL shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Guggenheim cut their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Oppenheimer restated an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Down 4.1 %

Shares of ZNTL stock opened at $3.06 on Monday. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.66 and a 12-month high of $18.07. The firm has a fifty day moving average of $3.34 and a 200-day moving average of $3.68. The company has a market capitalization of $218.07 million, a price-to-earnings ratio of -1.23 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.